



1653/4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 22 2001

TECH CENTER 1600/2900

Inventor's name:

IKONOMIDOU, Hrissanthi

Serial No. : 09/830,354

Filed : 25 April 2001

Title: NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. _____.
- ☒ Copies of materials listed but not attached were cited in an International Search Report dated 14 February 2000; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed 14 June 2001.
- ☐ Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.
- ☐ Also included are the pending U.S. applications listed below, copies of which are attached:

FEES

- ☒ No fee is required for this Information Disclosure Statement because:
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
- ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
- ☐ This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.

- ☐ A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
- ☐ A check is attached: This Information Disclosure Statement is being filed after the mailing date of a notice of allowance under § 1.311 but before the payment of the issue fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.


CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT


If appropriate, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,


Jennifer Branigan
Registration No.40,921
Patent Agent

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: 20 August 2001

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DKT. NO. HRISS-1	SERIAL NO. 09/830354
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use several sheets if necessary)</p>		APPLICANT IKONOMIDOU	
		FILING DATE April 25, 2001	GROUP

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
AA	4885171	12/5/1989	SURENDRA SEHGAL N			
AB						
AC						
AD						
AE						
AF						
AG						

RECEIVED

AUG 22 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
AM	0778023	6/11/1997	EP				
AN	0432994	6/19/1991	EP				
AO							
AP							
AQ							
AR							
AS							
AT							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AU	S.BEN-ELIYAHU: "The NMDA receptor antagonist MK-801 blocks nonopioid stress induced analgesia and decreases tumor metastasis in the rat" PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY, vol 36, 1993, pg 293-298
AV	N.SEILER: "Polyamine sulfonamides with NMDA antagonist properties are potent calmodulin antagonists and cytotoxic agents" INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY vol 30 no. 3 March 1998 pg 393-406
AW	K.IGARASHI: "Antagonist properties of polyamines and bis(ethyl)polyamines at N-methyl-D-aspartate receptors" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS vol 272 no.3, 1995, pg 1101-1109
AX	I.CHAUDIEU: "D-Aspartic Bets Hydroxymate (DAH) an Antitumoral Drug, Acts on n-Methyl-D-Aspartate Receptors in Rat Brain" J.NEUROCHEM vol 61, 1993 supplement pg S255
AY	KYAMADA: "Clinical and experimental studies on the antileukemic action of L-asparaginase" COLLOQ.INT.CENT.NAT.RECH.SCI. no. 197, 1971, pg 311-322
AZ	
Examiner	
Date Considered	